Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino M.CCho B.-CKim J.-HMazières JVansteenkiste JLena HCorral Jaime JGray J.EPowderly JChouaid CBidoli PWheatley-Price PPark KSoo R.AHuang YWadsworth CDennis P.ARizvi N.APaz-Ares Rodriguez LNovello SHiret SSchmid PLaack ECalifano RMaemondo MKim S.-WChaft JVicente Baz DBerghmans TKim D.-WSurmont VReck MHan J.-YHolgado Martin EBelda Iniesta COe YChella AChopra ARobinet GSoto Parra HThomas MCheema PKatakami NSu W.-CKim Y.-CWolf JLee J.-SSaka HMilella MRamos Garcia ISibille AYokoi TKang E.JAtagi SSpaeth-Schwalbe ENishio MImamura FGabrail NVeillon RDerijcke SMaeda TZylla DKubiak KSantoro AUy M.NLucien Geater SItaliano AKowalski DBarlesi FChen Y.-MSpigel DChewaskulyong BGarcia Gomez RAlvarez Alvarez RCHIH-HSIN YANGHsia T.-CDenis FSakai HVincent MGoto KBosch-Barrera JWeiss GCanon J.-LScholz CAglietta MKemmotsu HAzuma KBradbury PFeld RChachoua AJassem JJuergens RPalmero Sanchez RMalcolm AVrindavanam NKubota KWaller CWaterhouse DCoudert BMark ZSatouchi MChang G.-CHerzmann CChaudhry AGiridharan SHesketh PIkeda NBoccia RIannotti NHaigentz MReynolds JQuerol JNakagawa KSugawara STan E.HHirashima TGettinger SKato TTakeda KJuan Vidal OMohn-Staudner APanwalkar ADaniel DKobayashi KLadrera G.E.ISchulte CSebastian MCernovska MCoupkova HHavel LPauk NSingh JMurakami SCsoszi TLosonczy GPrice AAnderson IIqbal MTorri VJuhasz EKhanani SKoubkova LLevy BPage RBocskei CCrinò LEinspahr DHagenstad CJuat NOverton LGarrison MSzalai ZATLANTIC Investigators2020-05-262020-05-2620181470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043475986&doi=10.1016%2fS1470-2045%2818%2930144-X&partnerID=40&md5=e5a4d9a64dc723014fb28cae887ec8eahttps://scholars.lib.ntu.edu.tw/handle/123456789/494922[SDGs]SDG3Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyjournal article10.1016/S1470-2045(18)30144-X295450952-s2.0-85043475986